Alvotech is aiming to bring a number of new products to global markets in the coming months. Today we were very pleased to announce Alvotech's latest marketing approval in Europe, of our first biosimilar in ophthalmology. We are working with strong commercial partners such as Advanz Pharma, STADA (DE) and Biogaran (FR). Together we aim to increase access to cost-effective vision-protective care for millions of patients in Europe. This is just the latest step in Alvotech's ongoing mission, to broaden access to vital biologic medicines globally. Biosimilars bring down the cost of biologic medicine and support the sustainability of our healthcare systems, freeing up resources for further advances and breakthroughs in therapy. #betteraccess #betterlives #Europe Alvotech's press release: https://ow.ly/2ESA50WJKw0
Biosimilars like this are essential to making advanced treatments more accessible while easing pressure on healthcare systems. A big win for patients and providers alike.
Congrats Róbert! 🎉
Róbert Wessman. Excellent strategic marketing partnership. Wishing Alvotech continued success in driving and delivering accessible and affordable healthcare sustainability globally. Congratulations on this impactful achievement.
A big step for access — biosimilars help more patients benefit while easing healthcare costs.
Congrats Mr Wessman!
Congratulations!!
Congratulations!
Congratulations!
Really good news - well done to the Alvotech team 🙌
Leading Biopharmaceutical Operations with Strategic Quality, Compliance and Business Development Expertise
2moGreat to see the projects becoming commercial and successful.